Patent ID: 11047867

Abstract:
The present invention relates to an in vitro method for determining the risk of developing Alzheimer's disease or a cognitive disorder similar to said disease, an in vitro method for designing a personalized therapy in a subject suffering from mild cognitive impairment and an in vitro method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's or a cognitive disorder similar to said disease based on determining, in a sample from the subject, the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant. The invention also relates to the use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease. Finally, the invention relates to a kit comprising a reagent capable of determining the level of phosphorylation in threonine residues of E2F4 protein and the use of said kit.